Kite announces axicabtagene ciloleucel (Yescarta®) CAR T-cell therapy improved event-free survival over chemotherapy plus stem cell transplant in second-line relapsed or refractory large B-cell lymphoma

RCT (n=359) of single infusion vs standard of care reports the study met the primary endpoint of event-free survival (HR 0.398, p <0.0001). Overall survival data are immature at this time. Regulatory submissions are planned for this new indication.

Source:

Biospace Inc.